- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
- Interventions
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
- Drug · Other
- Lead sponsor
- ITM Solucin GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 14
- States / cities
- Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
- Conditions
- Neuroendocrine Tumors
- Interventions
- 131-I MIBG and 111-In pentetreotide, 131-I MIBG and In-111 DOTATATE
- Other
- Lead sponsor
- David Bushnell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
- Interventions
- Lutetium Lu 177-Edotreotide, Amino Acid Solution
- Drug · Other
- Lead sponsor
- ITM Solucin GmbH
- Industry
- Eligibility
- 24 Months to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
- Interventions
- 177Lu-DOTATOC
- Drug
- Lead sponsor
- Excel Diagnostics and Nuclear Oncology Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Interventions
- 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT)
- Drug · Procedure
- Lead sponsor
- Sue O'Dorisio
- Other
- Eligibility
- 1 Year to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography
- Procedure · Radiation · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
- Interventions
- Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Gallium Ga 68-DOTATATE, Positron Emission Tomography, Questionnaire Administration
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Drug · Other
- Lead sponsor
- ITM Solucin GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more
- Conditions
- Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography
- Procedure · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 8 more